Compare Msci Inc (MSCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Neurocrine Biosciences Inc — how do they compare? Msci Inc trades at $562.19 (market cap $40.38B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Msci Inc is far larger — about 2.8× Neurocrine Biosciences Inc's market cap, and Msci Inc pays a 1.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MSCI | NBIX | |
|---|---|---|
Market Cap | $40.38B | $14.36B |
Volume | 414,140 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $643.83 | $185.50 |
52-Week Low | $511.84 | $123.10 |
Typical Hold Time | 82 Days | 23 Days |
Enterprise Value | $46.54B | $14.37B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $555.38, up 0.08% on the day, with a neutral technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed slightly. Analyst sentiment is bullish with a 74% buy rating and a $701.71 consensus price target, suggesting significant upside. The company maintains robust cash flow from operations at $1.59B in 2025.
Outlook remains positive due to high profitability and analyst confidence, but risks include elevated valuation multiples and high long-term debt of $4.51B. The upcoming Q3 2026 earnings call on October 20, 2026, will be a key catalyst. Investors should weigh the strong growth trajectory against debt levels and market volatility.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
